Ketamine Therapy and Medicaid Coverage: A State-by-State Guide (2026)

If you rely on Medicaid and are considering ketamine therapy for treatment-resistant depression, PTSD, chronic pain, or another qualifying condition, the coverage question is almost certainly your first obstacle. The short answer is frustrating but important: most state Medicaid programs cover Spravato (FDA-approved esketamine nasal spray) with prior authorization, but very few cover traditional IV or IM ketamine infusions for mental health — those are almost universally classified as investigational. This guide walks through how Medicaid treats each form of ketamine, what coverage looks like in 10 high-population states, and a detailed look at Arkansas Medicaid, where patients most often ask us this question.

How Medicaid Covers Ketamine Therapy

Medicaid is a joint federal-state program, which means coverage rules are set state-by-state within broad federal guidelines. For ketamine specifically, three facts shape everything downstream.

First, racemic ketamine — the compound used for IV infusions, IM injections, compounded nasal spray, and sublingual troches — is FDA-approved only as an anesthetic. Its use for depression, anxiety, PTSD, OCD, bipolar depression, and chronic pain is off-label. Medicaid programs generally reimburse off-label uses only when there is strong published evidence supporting the indication and a specific state policy authorizing coverage. While the clinical evidence for ketamine in treatment-resistant depression has grown substantially over the past decade, most state Medicaid agencies still classify psychiatric ketamine infusions as investigational or experimental and do not reimburse for them. A handful of states have narrow coverage for ketamine infusions in specific pain syndromes (for example, complex regional pain syndrome), but this is the exception rather than the rule.

Second, Spravato (esketamine, the S-enantiomer of ketamine) is a distinctly different coverage question. The FDA approved Spravato in 2019 for treatment-resistant depression, and in 2020 it was additionally approved for major depressive disorder with acute suicidal ideation. Because it is on-label, nearly every state Medicaid formulary includes Spravato on its specialty drug tier with prior authorization. Typical prior authorization criteria require documentation that the patient has tried and failed at least two oral antidepressants from different classes, that the prescribing provider is certified under the Spravato REMS program, and that administration takes place in a REMS-certified clinic where the patient can be monitored for at least two hours after dosing.

Third, coverage details vary meaningfully from state to state. Arkansas Medicaid treats Spravato differently than California Medi-Cal; Medi-Cal treats it differently than New York Medicaid or Texas Medicaid. The variation shows up in the number of antidepressant trials required before authorization, the preferred-drug-list tier, the copay structure for managed-care members, and the rules about which clinics qualify for billing. That is why the state-by-state table in the next section is important — and why we always recommend calling your state Medicaid office or your managed-care plan directly before scheduling treatment.

Fourth, worth noting for 2026: the 2024 CMS Mental Health Parity Final Rule, which took effect for Medicaid managed-care plans in 2025, requires stricter parity between mental health and medical/surgical benefits. This has pushed several state Medicaid programs to streamline prior authorization for FDA-approved mental health medications, including Spravato. It has not, so far, changed coverage for off-label racemic ketamine infusions — parity does not compel coverage of off-label uses that the plan also declines to cover on the medical side. But the rule is worth watching, because continued parity enforcement could eventually prompt some state programs to reconsider ketamine infusion coverage where clinical evidence is strongest.

State-by-State Coverage

The table below summarizes Medicaid coverage in 10 high-population states. Coverage of racemic IV/IM ketamine for mental health is essentially universal as "not covered." Coverage of Spravato is essentially universal as "covered with prior authorization," with variation in the specific PA criteria. For pain indications, a few states evaluate ketamine infusions case-by-case.

Important caveat before you read the table: state Medicaid formulary and coverage policies change multiple times per year. The entries below reflect our best reading of published policy as of April 2026, but we have flagged every row with a "verify with state Medicaid office" disclaimer because billing reality — what actually gets paid when a claim is submitted — is the only ground truth. Do not make treatment decisions based on this table alone.

| State | IV/IM Ketamine | Spravato (Esketamine) | Prior Auth Required | Source / Notes | |---|---|---|---|---| | Arkansas | Not covered (investigational) | Covered | Yes — 2+ failed antidepressants | AR DHS Medicaid Specialty Drug Formulary — policy as of 2026-04-17, verify with state Medicaid office | | California (Medi-Cal) | Not typically covered | Covered | Yes — step therapy via Medi-Cal Rx | Medi-Cal Rx Contract Drug List — policy as of 2026-04-17, verify with state Medicaid office | | Florida | Not covered | Covered | Yes | FL AHCA Preferred Drug List — policy as of 2026-04-17, verify with state Medicaid office | | Georgia | Not covered | Covered | Yes | GA DCH Medicaid Pharmacy — policy as of 2026-04-17, verify with state Medicaid office | | Michigan | Limited off-label coverage possible for chronic pain (case-by-case) | Covered | Yes | MI MDHHS Medicaid Provider Manual — policy as of 2026-04-17, verify with state Medicaid office | | New York | Not covered | Covered | Yes — fee-for-service and managed care | NY State Medicaid Pharmacy Program PDL — policy as of 2026-04-17, verify with state Medicaid office | | North Carolina | Not covered | Covered | Yes | NC DHHS Medicaid Pharmacy — policy as of 2026-04-17, verify with state Medicaid office | | Ohio | Not covered | Covered | Yes | OH Department of Medicaid Unified PDL — policy as of 2026-04-17, verify with state Medicaid office | | Pennsylvania | Not covered | Covered | Yes | PA DHS Medical Assistance Pharmacy — policy as of 2026-04-17, verify with state Medicaid office | | Texas | Not covered | Covered | Yes | TX HHSC Medicaid Provider Procedures Manual — policy as of 2026-04-17, verify with state Medicaid office |

Coverage policies change frequently. Verify current coverage with your state Medicaid office or your clinic's billing team before scheduling treatment. The combination of fee-for-service rules, managed-care plan variations, and ongoing parity-driven updates means the only reliable answer for your specific case comes from a benefits verification call.

A few patterns are worth calling out from the table:

• Step therapy is near-universal for Spravato. Every state we surveyed requires documented failure of at least two oral antidepressants, usually from different mechanistic classes (for example, an SSRI and an SNRI, or an SSRI and an atypical antidepressant like bupropion or mirtazapine). A few states require three failed trials. The clinical rationale is that Spravato is expensive and carries REMS-level safety requirements, so it should be reserved for patients who have not responded to first-line treatment.
• Managed care adds a layer. Most states deliver Medicaid through managed-care organizations (MCOs) like Centene, Humana, Molina, or Blue Cross affiliates. Each MCO may have slightly different PA criteria or preferred provider networks on top of the state's baseline rules. Always confirm coverage with both the state Medicaid office and your specific MCO.
• REMS site requirements are non-negotiable. Spravato can only be administered at a REMS-certified facility, and only by a REMS-certified prescriber. If your current psychiatrist is not REMS-certified, you will need a referral to a clinic that is. Medicaid will not cover Spravato administered outside the REMS framework.
• Michigan is a mild outlier because Medicaid has historically approved ketamine infusions on a case-by-case basis for specific chronic pain conditions (most commonly complex regional pain syndrome), though not for psychiatric indications. This is not a blanket coverage promise — it requires detailed documentation and pre-authorization — but it is a path that a pain-management-focused clinic can sometimes navigate.

How copays and administration fees actually work

One of the most common points of confusion for Medicaid beneficiaries is the difference between the drug cost and the administration cost. For Spravato, those are billed separately, and the second line item is where surprise bills sometimes appear.

The drug itself. Spravato is billed under its specialty-pharmacy NDC. For Medicaid members in states where Spravato is on the preferred drug list, the member copay is typically $0 to $4 per dose — Medicaid rules cap pharmacy copays at very low levels, and most states waive them entirely for beneficiaries below certain income thresholds. The manufacturer, Janssen, also runs a patient assistance program that can cover copays for members who do not qualify for zero-copay coverage.

The administration and monitoring service. This is where costs can compound. Spravato requires a two-hour in-clinic observation period after each dose. Clinics bill this observation time using codes such as G2082 and G2083 (introduced specifically for Spravato) or, in some cases, standard evaluation-and-management codes alongside monitoring codes. Medicaid reimburses these codes at state-specific rates, and the member cost-share is usually small — but if the clinic is out of network for your managed-care plan, or if the PA authorization covered the drug but not the administration, you could be billed separately. Always confirm that both the drug and the administration service are authorized before your first appointment.

Maintenance-phase budgeting. The induction phase of Spravato involves roughly eight doses over four weeks. Once you transition to maintenance (weekly for weeks 5–8, then every one to two weeks indefinitely for responders), the administration burden continues — every dose requires a clinic visit and observation period. For Medicaid members this is usually fully covered, but if you change plans, move states, or lose Medicaid eligibility, you will need a continuity-of-care plan ready. Ask your clinic's billing team for a written estimate of what happens if your coverage lapses mid-treatment.

When plans change mid-year

Medicaid managed-care assignments and formulary tiers can change at the start of each benefit year (typically January 1 or July 1 depending on the state), and preferred drug list updates can take effect with as little as 30 days' notice. If you are stable on Spravato, watch for two risks: (1) a change in the preferred agent that requires a new prior authorization, and (2) a change in covered administration sites if your clinic's contract with the MCO is not renewed. Many clinics subscribe to Medicaid policy-change alerts and will flag upcoming changes for their active patients, but it pays to ask proactively each November and June.

Arkansas Medicaid Ketamine Coverage (Deep Dive)

Arkansas is where we field the most patient questions about Medicaid and ketamine, so it gets a dedicated section.

The bottom-line answer: Arkansas Medicaid does not cover IV or IM racemic ketamine for depression, anxiety, PTSD, OCD, or bipolar depression. These indications are classified as investigational on the Arkansas Medicaid Specialty Drug Formulary, which means claims submitted for ketamine infusions with psychiatric diagnosis codes will be denied. Arkansas Medicaid does cover Spravato (esketamine) with prior authorization, following the standard two-failed-antidepressant criterion common across state Medicaid programs.

What Arkansas Medicaid does cover

If you are an Arkansas Medicaid beneficiary with treatment-resistant depression, Spravato is your covered pathway. The practical requirements, as of April 2026, are:

1. Diagnosis. Your prescriber must document treatment-resistant depression (TRD) — defined by Arkansas Medicaid as major depressive disorder with inadequate response to at least two antidepressants of adequate dose and duration — or major depressive disorder with acute suicidal ideation or behavior. ICD-10 diagnosis codes (F33.2, F33.3, F32.9 with relevant modifiers) must appear on the prior authorization request.
2. Prior antidepressant trials. Arkansas Medicaid requires documentation of at least two adequate trials of oral antidepressants from different pharmacologic classes. "Adequate" typically means at least six weeks at a therapeutic dose. Common trial pairings that satisfy this requirement include an SSRI (such as sertraline, escitalopram, or fluoxetine) plus an SNRI (such as venlafaxine or duloxetine), or an SSRI plus an atypical (such as bupropion or mirtazapine). Your prescriber will attach medication-history documentation from the pharmacy benefits record.
3. REMS certification. The prescribing clinician must be enrolled in the Spravato REMS program, and administration must occur at a REMS-certified facility. Arkansas has a growing but still limited network of REMS-certified clinics — most are in Little Rock, Fayetteville, Rogers, Fort Smith, Jonesboro, and a handful of larger towns. Rural patients often face a drive of 60–120 miles to the nearest certified site.
4. Post-administration monitoring. Patients must remain on-site for at least two hours after each Spravato dose for blood pressure and sedation monitoring. The clinic bills Arkansas Medicaid for both the drug and the observation/administration service under separate codes.
5. Continuation criteria. After the induction phase (typically twice-weekly for four weeks), continuation into the maintenance phase (once weekly or every two weeks) requires documentation of clinical response — often measured with a PHQ-9 or similar standardized depression rating scale showing meaningful improvement.

Chronic pain indications

Arkansas Medicaid evaluates ketamine infusions for chronic pain separately from mental health indications. Coverage here is narrower and case-by-case. For conditions like complex regional pain syndrome (CRPS) or intractable neuropathic pain that has failed conventional management, a pain-medicine physician can submit a prior authorization request with supporting literature and clinical documentation. These requests are reviewed individually and approval is not routine. If you are pursuing this route, work with a pain-management specialist who has experience submitting ketamine PAs to Arkansas Medicaid.

Managed care: AR Total Care and Arkansas Works

Most Arkansas Medicaid beneficiaries are enrolled in either the traditional fee-for-service program, AR Total Care (the state's Provider-Led Arkansas Shared Savings Entity / PASSE program for members with complex behavioral health or developmental disability needs), or Arkansas Works (the Medicaid expansion program delivered through qualified health plans on the marketplace). Each track has slightly different administrative procedures:

• Fee-for-service Medicaid goes through the standard Arkansas Medicaid pharmacy PA process.
• AR Total Care / PASSE members submit PAs through their PASSE plan, which then coordinates with Arkansas Medicaid. This can add processing time but also gives members access to integrated behavioral health case management, which can help with the medical-necessity documentation.
• Arkansas Works members follow the PA rules of their specific qualified health plan (Ambetter, Blue Cross Blue Shield of Arkansas, etc.), which are generally aligned with Arkansas Medicaid but may have slightly different preferred specialty pharmacies or clinical criteria.

What to ask your provider

If you are pursuing Spravato through Arkansas Medicaid, bring this checklist to your first appointment:

• Are you a REMS-certified prescriber, and is this clinic a REMS-certified administration site?
• Do you bill Arkansas Medicaid directly, or do I need to see a different clinic for the billing relationship?
• What documentation from my past antidepressant trials do you need to support the prior authorization?
• How long does prior authorization typically take at this clinic? (Arkansas Medicaid generally turns around standard PAs in 24–72 business hours, but clinical documentation gathering can add a week or more.)
• If the PA is denied, what is your peer-to-peer review process?
• What is my expected copay structure, and what are the administration fees? (For most Arkansas Medicaid members, Spravato has a low or zero copay when covered, but administration fees and observation-period fees can apply depending on plan and clinic.)
• If I am in AR Total Care, have you billed ketamine treatments through the PASSE system before?
• What happens at session six, twelve, and beyond — what continuation criteria do you use?

Frequently Asked Questions

Does Arkansas Medicaid cover ketamine infusion for depression? No. Arkansas Medicaid currently classifies IV and IM racemic ketamine for depression and other mental health indications as investigational and does not reimburse for it. Patients needing ketamine-based treatment through Arkansas Medicaid are generally limited to Spravato (esketamine), which is covered with prior authorization. Policy is subject to change — verify directly with the Arkansas Department of Human Services or your Medicaid managed-care plan.

Does Arkansas Medicaid cover Spravato (esketamine)? Yes, with prior authorization. Spravato is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and Arkansas Medicaid includes it on its specialty drug formulary. Coverage typically requires documentation that the patient has tried and failed at least two different oral antidepressants at adequate doses and durations. Spravato must be administered in a REMS-certified clinic.

What prior authorization is needed for ketamine coverage? For Spravato, most state Medicaid programs require: (1) a diagnosis of treatment-resistant depression or MDD with suicidal ideation, (2) documented trials of two or more antidepressants from different classes at therapeutic doses, (3) confirmation the prescriber is REMS-certified, and (4) administration in a REMS-certified site. Racemic ketamine infusions typically do not qualify for prior authorization because they are considered off-label.

Which states' Medicaid programs cover ketamine? Nearly every state Medicaid program covers Spravato for treatment-resistant depression with prior authorization, because it is FDA-approved. Coverage of racemic IV or IM ketamine for mental health is rare — most state Medicaid programs consider it investigational. Some states, such as Michigan, cover ketamine infusions for narrow pain indications (for example, complex regional pain syndrome) on a case-by-case basis. Always verify current policy with the state Medicaid office or your managed-care plan.

Is ketamine infusion considered investigational by Medicaid? For mental health indications, yes — most state Medicaid programs label IV and IM racemic ketamine as investigational or experimental for depression, anxiety, PTSD, and OCD. The rationale is that racemic ketamine is used off-label for psychiatric care (its FDA approval is as an anesthetic), and Medicaid generally does not reimburse off-label uses without strong evidence and a specific policy. Spravato, which is FDA-approved, is treated differently and is covered.

Does Medicaid cover at-home ketamine therapy? No. At-home sublingual ketamine programs — which typically involve compounded troches or rapid-dissolve tablets mailed to the patient — are not covered by any state Medicaid program we are aware of. These programs are almost always self-pay, and compounded ketamine is not on Medicaid formularies. Medicaid coverage for ketamine is limited to Spravato administered in a REMS-certified clinical setting, and in rare cases to ketamine infusions for specific pain indications.

What if my state Medicaid denies ketamine coverage — what are my options? You have several paths: (1) file a formal appeal (see the next FAQ), (2) request a peer-to-peer review between your provider and the Medicaid medical director, (3) ask your prescriber whether Spravato is clinically appropriate as a covered alternative, (4) explore self-pay pricing — many clinics offer sliding-scale fees, package discounts, or financing through CareCredit or PatientFi, and (5) use HSA/FSA dollars if you have another plan alongside Medicaid. Some nonprofit foundations also offer grants for patients with treatment-resistant depression.

Can I appeal a Medicaid denial for ketamine therapy? Yes. Every state Medicaid program is required by federal law to provide an appeals process. The typical steps are: (1) request the written denial letter, which must state the specific reason for denial, (2) file a written appeal within the deadline (usually 30 to 90 days, varies by state), (3) submit supporting documentation including your prescriber's letter of medical necessity, records of failed prior treatments, peer-reviewed clinical evidence, and treatment guidelines, and (4) if the internal appeal is denied, request a fair hearing with an administrative law judge. Legal aid organizations and patient advocacy groups, including the National Alliance on Mental Illness (NAMI) and state-specific disability rights organizations, can help with appeals. Keep copies of every submission and note every deadline in writing.

Next Steps

• Ketamine insurance coverage (commercial plans) — if you also have private insurance or are considering switching plans
• Ketamine cost guide — out-of-pocket pricing if your Medicaid denies coverage
• Find a ketamine clinic — filter for providers who accept Medicaid or offer sliding-scale fees
• Spravato (esketamine) treatment details — the FDA-approved option most state Medicaid programs cover
• Ketamine payment plans and financing — CareCredit, PatientFi, HSA/FSA, and sliding-scale options

State Medicaid resources (verify coverage directly):

• Arkansas: humanservices.arkansas.gov/divisions-shared-services/medical-services/
• California (Medi-Cal Rx): medi-calrx.dhcs.ca.gov
• Florida (AHCA): ahca.myflorida.com/medicaid
• Georgia (DCH): medicaid.georgia.gov
• Michigan (MDHHS): michigan.gov/mdhhs/assistance-programs/medicaid
• New York: health.ny.gov/health_care/medicaid
• North Carolina (DHHS): medicaid.ncdhhs.gov
• Ohio: medicaid.ohio.gov
• Pennsylvania (DHS): dhs.pa.gov
• Texas (HHSC): hhs.texas.gov/services/health/medicaid-chip

References

1. CMS Mental Health Parity Final Rule (2024). Centers for Medicare & Medicaid Services. https://www.cms.gov/newsroom/fact-sheets/2024-mental-health-parity-final-rule
2. Arkansas Department of Human Services — Medicaid Provider Manual, Pharmacy and Specialty Drug Section. https://humanservices.arkansas.gov/divisions-shared-services/medical-services/
3. Spravato (Esketamine) REMS Program. https://www.spravatorems.com/
4. FDA Drug Approval Label for Spravato (esketamine). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf
5. Kaiser Family Foundation — Medicaid and Behavioral Health State Profiles. https://www.kff.org/medicaid/
6. Treatment-Resistant Depression and the Evolving Medicaid Policy Landscape. JAMA Psychiatry (perspective, 2024). https://jamanetwork.com/journals/jamapsychiatry
7. Medi-Cal Rx Contract Drugs List and Prior Authorization Criteria. California Department of Health Care Services. https://medi-calrx.dhcs.ca.gov/home/cdl
8. Texas Medicaid Provider Procedures Manual — Outpatient Drug Services. Texas Health and Human Services Commission. https://www.tmhp.com/topics/medicaid
9. New York State Medicaid Pharmacy Program — Preferred Drug List. New York State Department of Health. https://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm
10. Medicaid Coverage of Behavioral Health Services — Issue Brief. Kaiser Family Foundation (2023). https://www.kff.org/mental-health/issue-brief/medicaid-coverage-of-behavioral-health-services/